[go: up one dir, main page]

CN112638899A - 一类具有免疫调节功能的芳香化合物的制备和应用 - Google Patents

一类具有免疫调节功能的芳香化合物的制备和应用 Download PDF

Info

Publication number
CN112638899A
CN112638899A CN201980051399.7A CN201980051399A CN112638899A CN 112638899 A CN112638899 A CN 112638899A CN 201980051399 A CN201980051399 A CN 201980051399A CN 112638899 A CN112638899 A CN 112638899A
Authority
CN
China
Prior art keywords
group
substituted
unsubstituted
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980051399.7A
Other languages
English (en)
Other versions
CN112638899B (zh
Inventor
张毅
邓建稳
冯志勇
黄磊
江磊
路小丽
尚珂
寿建勇
汪兵
徐雪丽
徐圆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Ennovabio Pharmaceuticals Co Ltd
Original Assignee
Shanghai Ennovabio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810865177.6A external-priority patent/CN110790770A/zh
Priority claimed from CN201910503368.2A external-priority patent/CN112062780A/zh
Application filed by Shanghai Ennovabio Pharmaceuticals Co Ltd filed Critical Shanghai Ennovabio Pharmaceuticals Co Ltd
Publication of CN112638899A publication Critical patent/CN112638899A/zh
Application granted granted Critical
Publication of CN112638899B publication Critical patent/CN112638899B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种具有式(1)结构的免疫调节作用的芳香化合物、制备方法和其在调节免疫，抑制PD‑1/PD‑L1方面的用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980051399.7A 2018-08-01 2019-08-01 一类具有免疫调节功能的芳香化合物的制备和应用 Active CN112638899B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810865177.6A CN110790770A (zh) 2018-08-01 2018-08-01 一类具有免疫调节功能的芳香胺化合物的制备和应用
CN2018108651776 2018-08-01
CN201910503368.2A CN112062780A (zh) 2019-06-11 2019-06-11 一类具有免疫调节功能的芳香化合物的制备和应用
CN2019105033682 2019-06-11
PCT/CN2019/098925 WO2020025030A1 (zh) 2018-08-01 2019-08-01 一类具有免疫调节功能的芳香化合物的制备和应用

Publications (2)

Publication Number Publication Date
CN112638899A true CN112638899A (zh) 2021-04-09
CN112638899B CN112638899B (zh) 2023-09-05

Family

ID=69231502

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980051399.7A Active CN112638899B (zh) 2018-08-01 2019-08-01 一类具有免疫调节功能的芳香化合物的制备和应用

Country Status (4)

Country Link
US (1) US20210347785A1 (zh)
EP (1) EP3831823A4 (zh)
CN (1) CN112638899B (zh)
WO (1) WO2020025030A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005374A1 (en) 2016-06-27 2018-01-04 Chemocentryx, Inc. Immunomodulator compounds
AU2018306619B2 (en) 2017-07-28 2022-06-02 Chemocentryx, Inc. Immunomodulator compounds
KR102670486B1 (ko) 2017-08-08 2024-05-28 케모센트릭스, 인크. 마크로사이클릭 면역조절제
EP3755311A4 (en) 2018-02-22 2021-11-10 ChemoCentryx, Inc. INDANAMINE AS PD-L1 ANTAGONISTS
MX2021013819A (es) 2019-05-15 2022-02-10 Chemocentryx Inc Compuestos de triarilo para el tratamiento de enfermedades asociadas a pd-l1.
BR112021023750A2 (pt) 2019-06-20 2022-01-11 Chemocentryx Inc Compostos para tratamento de doenças pd-l1
MX2022000318A (es) 2019-07-10 2022-02-10 Chemocentryx Inc Indanos como inhibidores de pd-l1.
MX2022004450A (es) * 2019-10-16 2022-05-03 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
CN114585359B (zh) 2019-10-16 2025-08-12 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯酰胺
HUE069128T2 (hu) 2019-12-06 2025-02-28 Vertex Pharma Szubsztituált tetrahidrofurán vegyületek mint nátriumcsatornák modulátorai
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
AU2022284886A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
CN115433210A (zh) * 2021-06-04 2022-12-06 上海轶诺药业有限公司 一类具有免疫调节功能的化合物的制备和应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046133A1 (en) * 2002-11-15 2004-06-03 Merck Sharp & Dohme Limited Amino-heterocycles as vr-1 antagonists for treating pain
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
WO2014052699A1 (en) * 2012-09-28 2014-04-03 Cephalon, Inc. Azaquinazoline inhibitors of atypical protein kinase c
WO2017112730A1 (en) * 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017184775A1 (en) * 2016-04-19 2017-10-26 The Regents Of The University Of California Erbb inhibitors and uses thereof
WO2018026971A1 (en) * 2016-08-03 2018-02-08 Arising International, Llc Symmetric or semi-symmetric compounds useful as immunomodulators
WO2018119286A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119266A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119263A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046133A1 (en) * 2002-11-15 2004-06-03 Merck Sharp & Dohme Limited Amino-heterocycles as vr-1 antagonists for treating pain
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
WO2014052699A1 (en) * 2012-09-28 2014-04-03 Cephalon, Inc. Azaquinazoline inhibitors of atypical protein kinase c
WO2017112730A1 (en) * 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017184775A1 (en) * 2016-04-19 2017-10-26 The Regents Of The University Of California Erbb inhibitors and uses thereof
WO2018026971A1 (en) * 2016-08-03 2018-02-08 Arising International, Llc Symmetric or semi-symmetric compounds useful as immunomodulators
WO2018119286A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119266A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119263A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers

Also Published As

Publication number Publication date
US20210347785A1 (en) 2021-11-11
EP3831823A1 (en) 2021-06-09
WO2020025030A1 (zh) 2020-02-06
CN112638899B (zh) 2023-09-05
EP3831823A4 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
CN112638899A (zh) 一类具有免疫调节功能的芳香化合物的制备和应用
CN113365995B (zh) 免疫调节剂，组合物及其方法
CN112159405B (zh) 吡啶并嘧啶酮类化合物及其应用
CN114901660B (zh) 可作为t细胞活化剂的经取代双环化合物
AU2016282289B2 (en) HPK1 inhibitors and methods of using same
CN112638900A (zh) 一类具有免疫调节功能的含n杂环化合物的制备和应用
KR101816942B1 (ko) 키누레닌 생성 억제 작용을 갖는 함질소 복소환 화합물
CN113637005A (zh) 用于癌症治疗的kras抑制剂
CA3149482A1 (en) Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
CN110790770A (zh) 一类具有免疫调节功能的芳香胺化合物的制备和应用
KR20180083421A (ko) 단백질 키나아제 억제제 및 이의 제조방법과 의학적 용도
EP2945623A1 (en) Hedgehog pathway signaling inhibitors and therapeutic applications thereof
TW202136242A (zh) Smarca降解劑及其用途
TW202227063A (zh) 治療癌症之方法
CN110156656B (zh) 五元杂芳环衍生物、其制备方法、药物组合物及应用
CN119013277A (zh) Tyk2降解剂和其用途
CN114641474B (zh) 一类具有免疫调节功能的含n杂环化合物的制备和应用
CN112062780A (zh) 一类具有免疫调节功能的芳香化合物的制备和应用
JP7710756B2 (ja) Ｃｔｌａ－４低分子分解剤及びその使用
CN115867557B (zh) 氮杂卓类稠环化合物及其医药用途
WO2023104043A1 (zh) 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用
US20240262822A1 (en) Wdr5 inhibitors and modulators
WO2025085738A1 (en) Heterobifunctional compounds and methods of treating disease
EA048427B1 (ru) Замещенные бициклические соединения, применимые в качестве активаторов т-клеток
CN117642392A (zh) 一类具有免疫调节功能的化合物的制备和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant